Yet another country has begun battling with Vertex Pharmaceuticals (VRTX) over its cystic fibrosis medicines. In a new report, an independent Canadian advisory group has rejected the use of the Orkambi treatment over questions about both its cost and clinical effectiveness.

In reaching its conclusion, the Canadian Agency for Drugs and Technologies in Health cited uncertainty over clinical trials measuring the extent to which the drug improved patient health; a lack of studies gauging the effect Orkambi has on a need for lung transplants or survival; and no statistically significant improvements in health-related quality of life based on patient questionnaires, among other things.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy